MXPA03010019A - COMPOSICIoN PARA TRATAR EL ESTREnIMIENTO INDUCIDO POR FaRMACOS CON 15-CETO-PROSTAGLANDINAS. - Google Patents

COMPOSICIoN PARA TRATAR EL ESTREnIMIENTO INDUCIDO POR FaRMACOS CON 15-CETO-PROSTAGLANDINAS.

Info

Publication number
MXPA03010019A
MXPA03010019A MXPA03010019A MXPA03010019A MXPA03010019A MX PA03010019 A MXPA03010019 A MX PA03010019A MX PA03010019 A MXPA03010019 A MX PA03010019A MX PA03010019 A MXPA03010019 A MX PA03010019A MX PA03010019 A MXPA03010019 A MX PA03010019A
Authority
MX
Mexico
Prior art keywords
prostaglandins
keto
composition
treating drug
induced constipation
Prior art date
Application number
MXPA03010019A
Other languages
English (en)
Spanish (es)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23104042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA03010019(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of MXPA03010019A publication Critical patent/MXPA03010019A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA03010019A 2001-05-02 2002-04-26 COMPOSICIoN PARA TRATAR EL ESTREnIMIENTO INDUCIDO POR FaRMACOS CON 15-CETO-PROSTAGLANDINAS. MXPA03010019A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28772001P 2001-05-02 2001-05-02
PCT/JP2002/004223 WO2002089812A1 (en) 2001-05-02 2002-04-26 Composition for treating drug-induced constipation with 15-keto-prostaglandins

Publications (1)

Publication Number Publication Date
MXPA03010019A true MXPA03010019A (es) 2004-02-12

Family

ID=23104042

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010019A MXPA03010019A (es) 2001-05-02 2002-04-26 COMPOSICIoN PARA TRATAR EL ESTREnIMIENTO INDUCIDO POR FaRMACOS CON 15-CETO-PROSTAGLANDINAS.

Country Status (19)

Country Link
US (1) US6982283B2 (https=)
EP (1) EP1392318B1 (https=)
JP (1) JP4332353B2 (https=)
KR (1) KR100886598B1 (https=)
CN (1) CN1522147B (https=)
AR (2) AR035237A1 (https=)
AT (1) ATE355067T1 (https=)
AU (1) AU2002251554B2 (https=)
BR (1) BR0209327A (https=)
CA (1) CA2444103C (https=)
DE (1) DE60218451T2 (https=)
DK (1) DK1392318T3 (https=)
ES (1) ES2282408T3 (https=)
MX (1) MXPA03010019A (https=)
NO (1) NO335143B1 (https=)
NZ (1) NZ529187A (https=)
PT (1) PT1392318E (https=)
TW (1) TWI302100B (https=)
WO (1) WO2002089812A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1420794B1 (en) 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
TWI263505B (en) 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
NZ539582A (en) * 2002-10-23 2007-07-27 Sucampo Ag Prostaglandin compounds for the treatment of obesity
EP1575596B1 (en) * 2002-12-27 2016-06-22 Sucampo AG Derivatives of prostaglandins for treating irritable bowel syndrome and/or functional dyspepsia
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
RU2468800C2 (ru) * 2005-04-12 2012-12-10 Сукампо Аг Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
US9044510B2 (en) 2007-11-01 2015-06-02 Washington University Compositions and methods for treating pruritus
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
US8957024B2 (en) 2011-07-27 2015-02-17 Washington University Composition and methods for reducing opioid-induced pruritus
KR20140052389A (ko) 2012-10-24 2014-05-07 주식회사 아리바이오 해양 심층수 또는 염지하수로부터 제조된 고경도의 미네랄 워터를 포함하는 변비 예방, 개선 또는 치료용 조성물
US20140116916A1 (en) 2012-10-31 2014-05-01 2294719 Ontario Limited Therapy for Constipation
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
CN105777601A (zh) * 2014-12-26 2016-07-20 中国人民解放军第二军医大学 一种前列地尔衍生物及其药物制剂
AU2017241904A1 (en) * 2016-03-29 2018-10-18 Colonaryconcepts Llc Formulations for treating constipation
JP6957610B2 (ja) * 2016-10-06 2021-11-02 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 医薬品用途のための多層ビーズ

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1581886A (en) * 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
ES2051862T3 (es) * 1987-10-02 1994-07-01 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para producir un medicamento que tiene un efecto catartico.
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
TW224942B (https=) 1990-04-04 1994-06-11 Adka Ueno Kk
ATE174221T1 (de) * 1990-05-01 1998-12-15 R Tech Ueno Ltd Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
WO1997047595A1 (en) 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
ATE387204T1 (de) * 2001-05-18 2008-03-15 Sucampo Ag Zusammensetzung mit induzierendem kathartischen effekt

Also Published As

Publication number Publication date
CA2444103A1 (en) 2002-11-14
WO2002089812A1 (en) 2002-11-14
CN1522147A (zh) 2004-08-18
TWI302100B (en) 2008-10-21
JP4332353B2 (ja) 2009-09-16
KR100886598B1 (ko) 2009-03-05
ATE355067T1 (de) 2006-03-15
ES2282408T3 (es) 2007-10-16
AU2002251554B2 (en) 2007-05-24
NO20034864D0 (no) 2003-10-31
US20030073746A1 (en) 2003-04-17
PT1392318E (pt) 2007-05-31
CN1522147B (zh) 2010-05-12
US6982283B2 (en) 2006-01-03
NZ529187A (en) 2005-10-28
CA2444103C (en) 2010-06-08
AR035237A1 (es) 2004-05-05
EP1392318B1 (en) 2007-02-28
BR0209327A (pt) 2004-07-20
NO335143B1 (no) 2014-09-29
DE60218451T2 (de) 2007-11-08
AR100696A2 (es) 2016-10-26
NO20034864L (no) 2003-12-23
DE60218451D1 (de) 2007-04-12
DK1392318T3 (da) 2007-06-25
EP1392318A1 (en) 2004-03-03
JP2004527567A (ja) 2004-09-09
KR20040008168A (ko) 2004-01-28

Similar Documents

Publication Publication Date Title
MXPA03010019A (es) COMPOSICIoN PARA TRATAR EL ESTREnIMIENTO INDUCIDO POR FaRMACOS CON 15-CETO-PROSTAGLANDINAS.
MXPA03007093A (es) Nueva composicion.
MXPA02001855A (es) Composicion mejorada de revestimiento.
ZA200301673B (en) Cathartic composition.
SI1627050T1 (sl) Varianta humicola grisea cbh1.1
GB0026018D0 (en) New composition
MXPA03009558A (es) Compuestos novedosos.
SG138459A1 (en) Immunosensor
ZA200301274B (en) Gasoline composition.
MXPA03009698A (es) Vacuna multivalente que comprende un antigeno vih y un antigeno vsh y/o un antigeno vph.
MXPA03007693A (es) Composicion para la piel.
GB0111679D0 (en) Fuel composition
MXPA03004993A (es) Composiciones de policarbonato.
ZA200107863B (en) Candle composition.
EP1379245A4 (en) 1, 4, 5, 6-TETRAHYDROPYRAZOLO- 3, 4-C-PYRIDINE-7-ONE AS FACTOR XA HEMMER
EG23378A (en) Composition.
EP1298175A4 (en) PRIMER COMPOSITION
MXPA03005569A (es) PROCEDIMIENTO MEJORADO PARA LA PREPARACION DE UN FARMACO ANTIMIGRAnOSO.
MXPA01000464A (es) Composicion.
MXPA03008077A (es) Composicion humedecedora para la piel..
MX238286B (es) Composicion suavizante.
MXPA03004242A (es) Nuevas fenilpiperazinas.
GB0219752D0 (en) Composition
ZA200301049B (en) Trichoderma Composition.
MXPA03006632A (es) Composicion solida.

Legal Events

Date Code Title Description
FG Grant or registration